Company intelligence / Profile preview

Xinlitai Pharmaceutical

Ownership: Private
Development stage: Commercial

Overview

Xinlitai Pharmaceutical develops and commercializes a range of pharmaceutical products including APIs and finished dosage forms. The company has a strong focus on cardiovascular and cerebrovascular drugs and medical devices. It operates under GMP standards with an established quality management system. Its pipeline includes innovative therapies such as PCSK9 inhibitors for cholesterol management.

Therapeutic areas: OncologyEndocrinologyRheumatologyCardiovascularInfectious Diseases
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Drug pipeline

4 assets

SAL0140

Clinical trial

Indications: Hypertension

3 more assets in the full pipeline.

Request access →

Partnerships

Shijiazhuang Zhonghui Pharmaceutical Packaging Co., Ltd.

Beyond the preview

Go deeper on Xinlitai Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xinlitai Pharmaceutical.

Explore the full profile